Atrial high-rate episodes (AHRE) detected by cardiac implantable electronic devices are frequently encountered in clinical practice [1,2] and are associated with an increased risk of atrial fibrillation (AF), stroke, and mortality [3]. However, patients with AHRE represent a clinically heterogeneous population and current assessment may not capture this variability. Few studies have examined whether distinct clinical phenotypes exist within AHRE populations [4], despite the potential value for refined risk stratification and management.
